NCT01386723View on ClinicalTrials.gov

End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia

TerminatedOBSERVATIONAL
Enrollment

35

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

January 31, 2017

Conditions
Immune Thrombocytopenia
Interventions
DRUG

Discontinuation of eltrombopag

Observation of subjects as they discontinue the use of eltrombopag

Trial Locations (1)

10065

Weill Cornell Medical College/New York Presbyterian Hospital, New York

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER